DeeptiBehlMD

Oncology • Sacramento, CA

Hematologic Oncology, Thoracic Cancer

Physician

Join to view full profile

Dr. Behl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Behl's full profile

Already have an account?

Office
2800 L St
Suite 300
Sacramento, CA 95816
Phone+1 916-453-3300

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2006 - 2009
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2003 - 2006
Christian Medical College LudhianaClass of 1996

Certifications & Licensure

CA State Medical License 2009 - 2025
MN State Medical License 2006 - 2010
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) Start of enrollment: 2019 Jul 26
Active, not recruiting
Phase 3
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer Start of enrollment: 2020 Aug 13
Recruiting
Phase 3
Ashwagandha for Cognitive Dysfunction Start of enrollment: 2023 Jan 01
Recruiting
Phase 2
Roles: Principal Investigator, Contact

Publications & Presentations

PubMed

[F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy.
Jelena Levi, Millie Das, Minal S Vasanawala, Deepti Behl, Martin Pomper
Journal of Nuclear Medicine. 2024-12-03
Palbociclib in Patients With Head and Neck Cancer and Other Tumors WithAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Francis P Worden, Evan Pisick, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer
JCO Precision Oncology. 2024-10-01
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer WithAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Timothy L Cannon, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Vi K Chiu
Journal of Clinical Oncology. 2024-09-20

Press Mentions

The Cancer Treatment Within YouNovember 20th, 2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member